Premium
Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics
Author(s) -
Centorrino Franca,
Masters Grace A.,
Talamo Alessandra,
Baldessarini Ross J.,
Öngür Dost
Publication year - 2012
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2257
Subject(s) - antipsychotic , metabolic syndrome , medicine , schizoaffective disorder , chlorpromazine , schizophrenia (object oriented programming) , population , medical record , psychiatry , pediatrics , psychosis , obesity , environmental health
Objective We evaluated prevalence and risk factors for metabolic syndrome in inpatients treated with antipsychotics, with or without other psychotropic drugs. Although the literature on metabolic syndrome in psychiatry has expanded in recent years, we seek to elucidate some of the remaining gaps by examining a severely and chronically ill population heavily treated with pharmacological agents. Methods With data from medical records of 589 adults hospitalized at McLean Hospital in 2010 and 2011, we used standard statistical analyses to characterize risks and covariates of metabolic syndrome. Results With prior antipsychotic treatment, prevalence of metabolic syndrome was 29.5%. The syndrome was strongly associated with being overweight (≥25 kg/m 2 in 60.1% of subjects), older age, longer treatment‐exposure, schizoaffective diagnosis (39.8%), more illness‐episodes or hospitalizations, polytherapy, and higher total daily chlorpromazine‐equivalent doses, but not sex. Notably, metabolic syndrome risk was greater among young, antipsychotic treated patients (15.5‐fold at age ≤25 years). Conclusions The findings extend information on the association of metabolic syndrome with antipsychotic treatment. Metabolic syndrome was found in 30% of antipsychotic‐exposed inpatients. Risk was surprisingly high in young persons and after brief treatment‐exposure, and psychotropic polytherapy increased risk. Copyright © 2012 John Wiley & Sons, Ltd.